Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Erythroleukemia in multiple myeloma. A case report].

R Streuli, W Voellmy

    Schweizerische Medizinische Wochenschrift
    |February 21, 1987
    PubMed
    Summary

    Cytotoxic agents, like melphalan, can increase the risk of secondary cancers, including acute nonlymphocytic leukemias. This case study highlights erythroleukemia developing in a multiple myeloma patient treated with melphalan.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Contribution to calcium treatment of pleural effusions in pulmonary tuberculosis.

    Schweizerische medizinische Wochenschrift·2010
    Same author

    [Anemia, subcutaneous bleeding and weight loss. Disseminated metastasizing, mucinous adenocarcinoma of the stomach].

    Praxis·2000
    Same author

    [Extrajudicial expert assessment--what is the basis for complaints against internists?].

    Praxis·1999
    Same author

    [Severe hepatocellular damage after administration of paracetamol and chlorzoxazone in therapeutic dosage].

    Praxis·1998
    Same author

    [Intracardiac "umbrella" with anemia].

    Schweizerische medizinische Wochenschrift·1998
    Same author

    [Convulsive seizure].

    Praxis·1997

    Area of Science:

    • Hematology
    • Oncology
    • Clinical Medicine

    Background:

    • Cytotoxic chemotherapy is associated with an increased risk of secondary malignancies.
    • Acute nonlymphocytic leukemias are the most common secondary malignancies reported.
    • Melphalan is a cytotoxic agent used in treating multiple myeloma.

    Observation:

    • A 74-year-old female with multiple myeloma received melphalan treatment for 19 months.
    • Erythroleukemia, a type of acute nonlymphocytic leukemia, developed 23 months after initiating melphalan therapy.
    • The secondary leukemia significantly outcompeted myeloma cells in the bone marrow.

    Findings:

    • The development of erythroleukemia in a multiple myeloma patient treated with melphalan.
    • Bone marrow analysis revealed the secondary malignancy had largely replaced myeloma cells.
    • Electrophoresis showed a diminished paraprotein level, reflecting the reduced myeloma burden.

    Implications:

    • This case underscores the potential for melphalan-induced secondary leukemias in multiple myeloma patients.
    • Close monitoring for secondary malignancies is crucial in patients undergoing long-term cytotoxic therapy.
    • Understanding the long-term risks of chemotherapy is vital for optimizing cancer treatment strategies.

    Related Experiment Videos